Twenty-two patients at high risk to reject renal allografts have been treated with fractionated total lymphoid irradiation (FTLI) prior to transplantation of primary (2), secondary (16) or tertiary (4) renal allografts. All patients undergoing retransplantation had rapidly rejected previous grafts. At 24 months following transplantation, 72% of grafts were functioning in the TLI group compared with a 38% graft function in an historical control group of recipients receiving secondary or tertiary grafts and treated with conventional immunosuppression. Important variables in determining success of transplantation following fractionated TLI include the dose of TLI, the interval from radiation to transplantation, and maintenance post-transplant immunosuppressive therapy. Optimal results were achieved with 2500 rads delivered in 100 rad fractions followed by transplantation within two weeks, and a tapering prednisone schedule and maintenance azathioprine post-transplantation. Seventeen patients had significant complications of the radiation treatment and there was one death, prior to transplantation, associated with pneumonitis. In vitro assessment of immune function demonstrated marked peripheral T cell depletion and loss of in vitro responsiveness to mitogen and allogeneic stimulation following FTLI. The administration of 4onor bone marrow at the time of transplantation did not produce chimerism. The results suggest that when properly utilized FTLI can produce effective adjunctive immunosuppression for clinical transplantation.
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r HE APPLICATION of the immunosuppressive effects lof ionizing irradiation to transplantation were first explored nearly 25 years ago when treatment of prospective renal allograft recipients with whole body irradiation was attempted. It was found that the irradiation dose required to produce allograft prolongation also produced such severe bone marrow and G-I toxicity that this approach was all but abandoned by the mid 1960s.'
Presented at the Annual Meeting of the American Surgical Association, Boston, Massachusetts, April 21- 23, 1982. Reprint Other less toxic applications of x-irradiation were directed at immunocompetent lymphoid cells. Experimental and clinical use of local graft irradiation,2 intralymphatic administration of radioisotopes,3 and extracorporeal irradiation of blood4 and lymph5 were all tested experimentally and clinically. The variability of radiation dose delivered and allograft prolongation achieved by these techniques limited their applicability to clinical transplantation. It was the Stanford group who first noted that patients treated with fractionated total nodal irradiation for Hodgkin's disease sustained a long-lasting impairment of cell-mediated immune functions.6 This led to a series of experimental studies in rodents,7'8 dogs,9"0 and primates" that demonstrated greatly delayed rejection of skin and vascularized solid organ allografts following a preparative protocol of fractionated total lymphoid irradiation. Additionally observed was the indefinite survival of skin allografts in FTLI-treated rodents given donor bone marrow simultaneously with the graft.'2 The animals were permanently chimeric, and graft-vs.-host disease did not occur. The lack of toxicity to the bone marrow and G-I tract using this experimental protocol while maintaining a strong immunosuppressive effect gave the impetus for further experimental studies and a clinical tnral of preparative FTLI in a group of renal transplant patients at a high risk of rejection of their grafts. Patients in renal failure who have rapidly rejected previous kidney grafts are at high risk of graft loss following retransplantation. In our experience, only 46% of patients who reject first transplants within one year will have functioning second grafts one year after re-transplantation. By four years this figure drops to 28% despite the use of antilymphocyte globulin and conventional prednisone and azathioprine therapy.'3 To improve results in this difficult group of patients, a more effective form of immunosuppression is required.
Since 1979 the authors have treated 22 patients at high risk for rejection of a renal allograft with total lymphoid irradiation prior to transplantation. FTLI was used primarily for its generalized immunosuppressive effect, but donor bone marrow cells were administered at the time of transplantation when it was logistically feasible. Azathioprine and prednisone were also administered post-transplant because there was an anticipated dissipation of the TLI effect with time.
rads daily fraction. The total dose delivered, however, ranged from 1050 to 4050 rads because of the delay between the completion of radiation and poor tolerance of radiation by some patients. Daily fraction was reduced to 100 rads after the first nine patients. Three patients received maintenance radiation ranging from 625 to 800 rads, 125 rads per fraction, twice weekly while they are waiting for a compatible cadaver kidney after the completion of planned radiation.
Radiation 
Complications of TLI
Only seven of 24 patients irradiated experienced uncomplicated and uninterrupted courses of preparative radiation therapy. Seventeen had complications that required an interruption oftheir radiation therapy of from three to 38 days. Six patients experienced leukopenia with WBC <2500; seven patients had severe gastrointestinal symptoms of anorexia, nausea, and vomiting, three of whom required hospitalization and nutritional support with intravenous hyperalimentation for periods of five to 14 days. Three additional patients had unexplained fever that ran a self-limited course (Table 2) .
Another patient developed bilateral pneumonitis after receiving 3000 rads. Bronchoscopy was performed for diagnostic purposes. The patient had a drug reaction and a cardiorespiratory arrest. She died before transplantation.
All patients experienced varying degrees ofweight loss and anemia throughout their radiation course. In general, radiation was tolerated less well in diabetic patients who seemed to experience more severe weight loss and gastrointestinal symptoms then their nondiabetic counterparts.
Immune Consequences of TLI
Serial determinations of immune function beginning prior to irradiation treatments and at weekly intervals thereafter were performed on peripheral blood of all patients (Fig. 1) . Total T-cell number as well as functional responses in vitro were assayed. Prior to any irradiation, T-cell numbers were normal with only a slight depression in functional responses (60 to 90% ofcontrol) (Fig. 1 ).
The consequence of increasing irradiation dose on circulating T-cell number was a dramatic decrease in the total circulating T-cell number with increasing dose ofradiation to 10-15% ofpretreatment values after 2500 rads. Despite T-cell depletion in the peripheral blood, the per cent oflymphocytes that formed sheep red blood cell rosettes remained constant throughout the course of irradiation. T-cell function, however, as assayed by response to mitogens or by responsiveness to allogeneic stimulation in a mixed lymphocyte culture, progressively decreased to a point prior to transplantation where 10-15% of control responsiveness was the rule. This decrease in responsiveness was not simply due to T-cell depletion. When the functional assays were performed, a constant number of lymphocytes were placed in culture. Because the percent of T cells did not change throughout the course of radiation therapy, there was When the two primary grafts are excluded, and only retransplants are analyzed and compared with the authors' past experience using conventional immunosuppressive therapy (Fig. 3) At six months the patient presented with a neck mass that was biopsied and diagnosed as a post-transplant lymphoma. Cultures for cytomegalovirus, Herpes simplex virus, and Epstein-Barr virus were all positive. Bone marrow aspiration at this time was also positive for tumor. The patient's immunosuppression was decreased, and he was treated with the antiviral drug acyclovir. The neck mass disappeared, the bone marrow became negative for tumor, and cultures for EB virus became negative. He maintained positive cultures for CMV. Six weeks later he was treated for a third rejection episode. This was followed by recrudescence of his lymphoma to which he ultimately succumbed. (Table 3) . Three protocols for post-transplant prednisone therapy were utilized. Fourteen patients received a standard tapering dose of prednisone beginning at 2 mg/kg/day tapered to 0.5 mg/kg/day by three-weeks post-transplant. Four patients received an accelerated taper of prednisone beginning at 2 mg/kg/day but tapered to 0.3 mg/kg/day by two weeks. Three patients did not receive a tapering schedule but were begun immediately post-transplant on a low dose of 0.4 mg/kg/ day. All patients received azathioprine titrated to their WBC and platelet counts. Usually this was between 1 and 1.5 mg/kg/day.
Five of the 14 patients who received the standard prednisone taper (Table 3) experienced acute rejection episodes within the first two months post-transplant. These five were the only patients in this group who had a significantly longer (p < 0.01) length of time between completion of the radiation course and transplantation-a problem that was necessitated by the prior unavailability of a crossmatch negative cadaveric kidney. During this time, immunologic recovery, as assayed by in vitro testing, was observed. In the group undergoing early rejection episodes, T-cell number had returned to near normal levels with partial recovery of MLC reactivity prior to transplantation when compared with the group that never experienced an acute rejection episode. It should be emphasized that the increase in T-cell number and MLC reactivity is a function of time and represents partial immunologic recovery from the immunosuppressive effects of radiation. All patients including those experiencing early rejection episodes, had been in cohort cultures performed in parallel. cpm patient cells X 100 cpm normal cells profoundly T-cell depleted with markedly depressed MLC responsiveness immediately following the course of FTLI (Fig. 1) .
A second important variable that may predispose to acute rejection episodes following preparative FTLI is the postoperative immunosuppressive regimen. All three patients given low-dose prednisone (0.4 mg/kg/day) from the day of transplant experienced acute rejection episodes within the first month. The dose of TLI and time interval in which it was delivered were not significantly different from the other groups (Table 1) . These three patients were successfully treated, have had no further rejection episodes, and currently have normal renal function 18, 19 and 38 months following transplantation.
A third group of patients received an accelerated tapering prednisone schedule following FTLI that began at 2 mg/kg/day tapering to 0.3 mg/kg by two weeks. None ofthese four patients have had any acute rejection episodes 17 to 21 months later.
One Year Follow-up Data Fourteen of the authors' 16 patients with functioning grafts, received their transplants more than one year ago. Of these 14 patients, three have biopsy-documented chronic rejection with serum creatinines of4.1, 3.5, and 2.4 mg/dl, and 11 have normal renal function (mean serum creatinine, 1.3 ± .3). The results ofimmune function studies performed one year following transplantation are shown in Table 4 . There is no significant difference in the per cent or number of T cells in the peripheral blood of those patients with chronic rejection and those with normal renal function. There is, however, a highly significant difference in the in vitro functional responsiveness of lymphocytes from patients within each group. Those patients with chronic rejection are highly mitogen and MLC reactive, whereas those with 
Discussion
Previous analysis of the authors' results'8'22'23 as well as others24 suggest that an important determinant of the success of secondary and tertiary transplantation is the duration of function of the first allograft. Those patients undergoing retransplantation who have lost a previous graft to acute rejection within the first several months following transplantation have a diminished chance of success when compared with either primary transplantation from the same donor source or retransplantation in patients who had maintained their first grafts for 12 months or more.'3 Other factors influencing success of retransplantation are donor source, recipients of secondary or tertiary cadaveric grafts having less successful outcome than living related grafts, patient age, older patients undergoing retransplantation doing less well then younger patients, and the presence of diabetes. Therefore, based on the authors' previous experience, the 22 There appears to be an important relationship between the total dose of TLI delivered and the pharmacologic immunosuppression given post-transplant. The authors' results suggest that 2500 rads of fractionated TLI followed by transplantation within two weeks of completion of the radiation course, and a postoperative immunosuppressive protocol of tapering prednisone and maintenance azathioprine therapy can achieve good patient and graft survival in an historically difficult group of patients.
The importance of the length of time between completion of radiation and transplantation is apparent (Table 1) 
